西藏药业: 西藏诺迪康药业股份有限公司2025年第一次临时股东大会决议公告

Meeting Details - The annual general meeting was held on September 2, 2025, at the company's office in Chengdu, Sichuan Province [1] - The meeting was presided over by Chairman Chen Dabing, and the voting method complied with the Company Law and Articles of Association [1] Attendance and Voting Results - The meeting had participation from ordinary shareholders and preferred shareholders with restored voting rights [1] - The voting results for the non-cumulative voting proposals showed a high approval rate, with the following details: - Proposal 1: 99.6975% approval from A-shareholders [1] - Proposal 2: 99.8543% approval from A-shareholders [1] - Proposal 3: 99.8271% approval from A-shareholders [1] - Proposal 4: 99.8574% approval from A-shareholders [1] Legal Compliance - The meeting's convening, procedures, and voting were confirmed to be in compliance with the Company Law, Shareholders' Meeting Rules, and other relevant regulations [2]